Early Real-World Experiences With Faricimab and Aflibercept 8mg

EP: 1.Navigating Step Therapy in nAMD and DME

EP: 2.Role of Biosimilars in nAMD and DME Step Therapy

EP: 3.Overview of the Newest Therapies for AMD and DME: Faricimab and Aflibercept 8mg

EP: 4.Aligning Clinical Trial Retreatment Criteria to Clinical Practice

EP: 5.Perspectives on Retinal Fluid Management in nAMD and DME

EP: 6.Perspectives on Loading Dose and Treatment Extension With New Therapies

EP: 7.Using Steroids in DME Treatment

EP: 8.Patient Selection for New nAMD and DME Therapies

Now Viewing

EP: 9.Early Real-World Experiences With Faricimab and Aflibercept 8mg

EP: 10.Safety Considerations for New Therapies

EP: 11.Promoting Treatment Adherence in nAMD and DME

Summary

Experts share their clinical experiences using second-generation therapeutics to manage retinal diseases. In early experiences with these drugs for neovascular AMD and DME, the feedback has been generally positive. The use of faricimab, particularly in challenging cases, has shown improvement in around one-third of patients, with another third showing similar outcomes to the previous treatment, aflibercept 2 milligram. High dose aflibercept 8mg has demonstrated efficacy in extending treatment intervals for many patients. While outcomes for the most difficult-to-treat patients are still being assessed by the experts, initial observations suggest improvement, albeit not drastically longer dosing intervals. Overall, the experts anticipate that results will align closely with those of faricimab, with roughly a third of patients experiencing significant improvement and another third seeing comparable outcomes to previous treatments.

This summary was AI-generated and edited for clarity.